ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2020-2-120-131ssmu-2869Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESРоль комплекса IL-33/ST2 в модуляции иммунного ответа при инфекционном эндокардите (обзор литературы)The role of IL-33/ST2 system in the modulation of the immune response in infective endocarditis (a literature review)https://orcid.org/0000-0002-0747-2495АсановМ. А.AsanovM. A.

мл. науч. сотрудникРоссия, 650002, г. Кемерово, Сосновый бульвар, 6

Россия, 650000, г. Кемерово, Ленинградский пр., 10

6, Sosnovy Blvd., Kemerovo, 650002, Russian Federation

10, Leningradsky Av., Kemerovo, 650000, Russian Federation

asmaks988@gmail.comhttps://orcid.org/0000-0002-3002-2863ПонасенкоА. В.PonasenkoA. V.

6, Sosnovy Blvd., Kemerovo, 650002, Russian Federation

Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ); Федеральный исследовательский центр угля и углехимии СО РАН (ФИЦ УУХ СО РАН)РоссияResearch Institute for Complex Issues of Cardiovascular Diseases; The Federal Research Center of Coal and Coal Chemistry of SB RASRussian FederationНаучно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний (НИИ КПССЗ)РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation202012072020192120131Copyright © Асанов М.А., Понасенко А.В., 20202020Асанов М.А., Понасенко А.В.Asanov M.A., Ponasenko A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/2869IL-33ST2интерлейкининфекционный эндокардитсердечно-сосудистые заболеваниясекреция белкаэкспрессия генаIL-33ST2interleukininfective endocarditiscardiovascular diseasesprotein secretiongene expressionРабота выполнена при поддержке комплексной программы фундаментальных научных исследований СО РАН в рамках фундаментальной темы НИИ КПССЗ № 0546-2015-0011 «Патогенетическое обоснование разработки имплантатов для сердечно-сосудистой хирургии на основе биосовместимых материалов, с реализацией пациент-ориентированного подхода с использованием математического моделирования, тканевой инженерии и геномных предикторов».ReferencesNaghavi M. Mortality and causes of death collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117–171. DOI: 10.1016/S0140-6736(14)61682-2.Naghavi M. Mortality and causes of death collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385 (9963): 117–171. DOI: 10.1016/S0140-6736(14)61682-2.Данилов А.И., Козлов Р.С., Козлов С.Н., Дехнич А.В. Практика ведения пациентов с инфекционным эндокардитом в Российской Федерации. Антибиотики и химиотерапия. 2017; 62 (1-2): 30–34. DOI: 10.24411/0235-2990-2017-00027.Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., Lukic M.L. IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research. 2012; 52 (1-2): 89–99. DOI: 10.1007/s12026-012-8283-9.Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., Lukic M.L. IL-33/ST2 axis in inflammation and immunopathology. Immunologic Research. 2012; 52 (1-2): 89–99. DOI: 10.1007/s12026-012-8283-9.Liu X., Hammel M., He Y., Tainer J.A., Jeng U.S., Zhang L., Wang S., Wang X. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl. Acad. Sci. USA. 2013; 110 (37): 14918–14923. DOI: 10.1073/pnas.1308651110. Bulletin of Siberian Medicine. 2020; 19 (2): 120–131Liu X., Hammel M., He Y., Tainer J.A., Jeng U.S., Zhang L., Wang S., Wang X. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl. Acad. Sci. USA. 2013; 110 (37): 14918–14923. DOI: 10.1073/pnas.1308651110. Bulletin of Siberian Medicine. 2020; 19 (2): 120–131Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 2008; 7 (10): 827–840. DOI: 10.1038/nrd2660.Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat. Rev. Drug Discov. 2008; 7 (10): 827–840. DOI: 10.1038/nrd2660.Gaca J.G., Sheng S., Daneshmand M.A., O’Brien S., Rankin J.S., Brennan J.M., Hughes G.C., Glower D.D., Gammie J.S., Smith P.K. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J. Thorac. Cardiovasc. Surg. 2011; 141: 98–106. DOI: 10.1016/j.jtcvs.2010.09.016.Резник И.И., Идов Э.М., Кисляк С.В., Зайцев Л.Н., Беллина Е.С. Современный инфекционный эндокардит: клинико-морфологическая эволюция, взаимосвязь с антифосфолипидным синдромом. Архив внутренней медицины. 2013; 1 (9): 49–59. DOI: 10.20514/2226-6704-2013-0-1-49-59.Scully I.L., Timofeyeva Y., Keeney D., Matsuka Y.V., Severina E., McNeil L.K., Nanra J., Hu G., Liberator P.A., Jansen K.U., Anderson A.S. Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. Vaccine. 2015; 33 (41): 5452–5457. DOI: 10.1016/j.vaccine.2015.08.029.Стасев А.Н., Рутковская Н.В., Кокорин С.Г., Левадин Ю.В. Сальмонелезный эндокардит митрального клапана: клиническое наблюдение. Комплексные проблемы сердечно-сосудистых заболеваний. 2017; 6 (2): 123–126. DOI: 10.17802/2306-1278-2017-2-123-126. (2)Holland T.L., Baddour L.M., Bayer A.S., Hoen B., Miro J.M., Fowler V.G. Infective endocarditis. Nat. Rev. Dis. Primers. 2016; 2: 16059. DOI: 10.1038/nrdp.2016.59.Понасенко А.В., Кутихин А.Г., Хуторная М.В., Южалин А.Е., Рутковская Н.В., Головкин А.С. Связь полиморфизмов гена TREM-1 с инфекционным эндокардитом. Инфекция и иммунитет. 2015; 5 (4): 331–338. DOI: 10.15789/2220-7619-2015-4-331-338.Golovkin A.S., Ponasenko A.V., Yuzhalin A.E., Salakhov R.R., Khutornaya M.V., Kutikhin A.G., Rutkovskaya N.V., Savostyanova Y.Y., Barbarash L.S. An association between single nucleotide polymorphisms within TLR and TREM-1 genes and infective endocarditis. Cytokine. 2015; 71 (1): 16–21. DOI: 10.1016/j.cyto.2014.08.001.Рахматулина М.Р., Барышков К.В., Абудуев Н.К. Проявлений гонококковой инфекции и тактика терапии заболевания с учетом антибиотикочувствительности N. gonorrhoeae в Архангельской области. Вестник дерматологии и венерологии. 2014; 6: 100–106. DOI: 10.25208/0042-4609-2014-0-6-100-106.Moreau K., Clemenceau A., Le Moing V., Messika-Zeitoun D., Andersen P.S., Bruun N.E., Skov R.L., Couzon F., Bouchiat C., Erpelding M.L., van Belkum A., Bossé Y., Duval X., Vandenesch F. Human genetic susceptibility to native valve Staphylococcus aureus endocarditis in patients with S. aureus bacteremia: Genome-Wide Association Study. Front. Microbiol. 2018; 9: 640. DOI: 10.3389/fmicb.2018.00640.Gaca J.G., Sheng S., Daneshmand M.A., O’Brien S., Rankin J.S., Brennan J.M., Hughes G.C., Glower D.D., Gammie J.S., Smith P.K. Outcomes for endocarditis surgery in North America: a simplified risk scoring system. J. Thorac. Cardiovasc. Surg. 2011; 141: 98–106. DOI: 10.1016/j.jtcvs.2010.09.016.Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarström C., Loos T., Kasprzycka M., Sørensen D.R., Nilsen H.R., Küchler A.M., Vatn M.H., Haraldsen G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 2010; 177 (6): 2804–2815. DOI: 10.2353/ajpath.2010.100378.Понасенко А.В., Головкин А.С., Григорьев Е.В. Значение системы комплемента и С5а субъединицы при формировании системного воспалительного ответа в послеоперационном периоде протезирования клапанов сердца пациентов с инфекционным эндокардитом. Фундаментальные исследования. 2014; 1 (10): 141–146.Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010; 10 (2): 103–110. DOI: 10.1038/nri2692.Scully I.L., Timofeyeva Y., Keeney D., Matsuka Y.V., Severina E., McNeil L.K., Nanra J., Hu G., Liberator P.A., Jansen K.U., Anderson A.S. Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. Vaccine. 2015; 33 (41): 5452–5457. DOI: 10.1016/j.vaccine.2015.08.029.Nile C.J., Barksby E., Jitprasertwong P., Preshaw P.M., Taylor J.J. Expression and regulation of interleukin-33 in human monocytes. Immunology. 2010; 130 (2): 172–180. DOI: 10.1111/j.1365-2567.2009.03221.x.Holland T.L., Baddour L.M., Bayer A.S., Hoen B., Miro J.M., Fowler V.G. Infective endocarditis. Nat. Rev. Dis. Primers. 2016; 2: 16059. DOI: 10.1038/nrdp.2016.59.Angeles-Martínez J., Posadas-Sánchez R., Llorente L., Alvarez-León E., Ramírez-Bello J., Villarreal-Molina T., Lima G., Cardoso-Saldaña G., Rodríguez-Pérez J.M., Pérez-Hernández N., Fragoso J.M., Posadas-Romero C., Vargas-Alarcón G. The rs7044343 polymorphism of the interleukin 33 gene is associated with decreased risk of developing premature coronary artery disease and central obesity, and could be involved in regulating the production of IL-33. PLoS One. 2017; 12 (1):Golovkin A.S., Ponasenko A.V., Yuzhalin A.E., Salakhov R.R., Khutornaya M.V., Kutikhin A.G., Rutkovskaya N.V., Savostyanova Y.Y., Barbarash L.S. An association between single nucleotide polymorphisms within TLR and TREM-1 genes and infective endocarditis. Cytokine. 2015; 71 (1): 16–21. DOI: 10.1016/j.cyto.2014.08.001.e0168828. DOI: 10.1371/journal.pone.0168828.Moreau K., Clemenceau A., Le Moing V., Messika-Zeitoun D., Andersen P.S., Bruun N.E., Skov R.L., Couzon F., Bouchiat C., Erpelding M.L., van Belkum A., Bossé Y., Duval X., Vandenesch F. Human genetic susceptibility to native valve Staphylococcus aureus endocarditis in patients with S. aureus bacteremia: Genome-Wide Association Study. Front. Microbiol. 2018; 9: 640. DOI: 10.3389/fmicb.2018.00640.De la Fuente М., MacDonald T.T., Hermoso M.A. The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015; 26 (6): 615–623. DOI: 10.1016/j.cytogfr.2015.07.017.Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarström C., Loos T., Kasprzycka M., Sørensen D.R., Nilsen H.R., Küchler A.M., Vatn M.H., Haraldsen G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 2010; 177 (6): 2804–2815. DOI: 10.2353/ajpath.2010.100378.Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell-tolls. Circ. Res. 2011; 108 (9): 1133–1145. DOI: 10.1161/CIRCRESAHA.110.226936.Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010; 10 (2): 103–110. DOI: 10.1038/nri2692.Lott J.M., Sumpter T.L., Turnquist H.R. New dog and new tricks: evolving roles for IL-33 in type 2 immunity. J. Leukoc. Biol. 2015; 97 (6): 1037–1048. DOI: 10.1189/jlb.3RI1214-595R.Nile C.J., Barksby E., Jitprasertwong P., Preshaw P.M., Taylor J.J. Expression and regulation of interleukin-33 in human monocytes. Immunology. 2010; 130 (2): 172–180. DOI: 10.1111/j.1365-2567.2009.03221.x.Verri W.A., Souto F.O., Vieira S.M., Almeida S.C.L., Fukada S.Y., Xu D., Alves- Filho J.C., Cunha T.M., Guerrero A.T., Mattos-Guimaraes R.B., Oliveira F.R., Teixeira M.M., Silva J.S., McInnes I.B., Ferreira S.H., Louzada-Junior P., Liew F.Y., Cunha F.Q. IL- 33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 2010; 69 (9): 1697–1703. DOI: 10.1136/ard.2009.122655.Angeles-Martínez J., Posadas-Sánchez R., Llorente L., Alvarez-León E., Ramírez-Bello J., Villarreal-Molina T., Lima G., Cardoso-Saldaña G., Rodríguez-Pérez J.M., Pérez-Hernández N., Fragoso J.M., Posadas-Romero C., Vargas-Alarcón G. The rs7044343 polymorphism of the interleukin 33 gene is associated with decreased risk of developing premature coronary artery disease and central obesity, and could be involved in regulating the production of IL-33. PLoS One. 2017; 12 (1): e0168828. DOI: 10.1371/journal.pone.0168828.Cui G., Qi H., Gundersen M.D., Yang H., Christiansen I., Sørbye S.W., Goll R., Florholmen J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol. Immunother. 2015; 64 (2): 181–190. DOI: 10.1007/s00262-014-1624-x.Колобов В.В. Интерлейкин-33 – ключевой посредник в реализации иммунного ответа. Цитокины и воспаление. 2011; 10 (3): 5–9.Fu A.K., Hung K.W., Yuen M.Y., Zhou X., Mak D.S., Chan I.C., Cheung T.H., Zhang B., Fu W.Y., Liew F.Y., Ip N.Y. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. PNAS. 2016; 113 (19): e2705–2713. DOI: 10.1073/pnas.1604032113.De la Fuente М., MacDonald T.T., Hermoso M.A. The IL-33/ST2 axis: Role in health and disease. Cytokine Growth Factor Rev. 2015; 26 (6): 615–623. DOI: 10.1016/j.cytogfr.2015.07.017.Theoharides T.C., Zhang B., Kempuraj D., Tagen M., Vasiadi M., Angelidou A., Alysandratos K.D., Kalogeromitros D., Asadi S., Stavrianeas N., Peterson E., Leeman S., Conti P IL-33 augments substance p-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA. 2010; 107 (9): 4448–4453. DOI: 10.1073/pnas.1000803107.Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell-tolls. Circ. Res. 2011; 108 (9): 1133–1145. DOI: 10.1161/CIRCRESAHA.110.226936.Queiroz G.A., Costa R.S., Alcantara-Neves N.M., Barreto M.L., Carneiro V.L., Figueredo C.A. IL33 and IL1RL1 variants are associated with asthma and atopy in a Brazilian population. Int. J. Immunogenet. 2017; 44 (2): 51–61. DOI: 10.1111/iji.12306. DOI: 10.1111/iji.12306.Lott J.M., Sumpter T.L., Turnquist H.R. New dog and new tricks: evolving roles for IL-33 in type 2 immunity. J. Leukoc. Biol. 2015; 97 (6): 1037–1048. DOI: 10.1189/jlb.3RI1214-595R.Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarstrome C., Loos T., Kasprzycka M., Sørensen D.R., Nilsen H.R., Küchler A.M., Vatn M.H., Haraldsen G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 2010; 177 (6): 2804–2815. DOI: 10.2353/ajpath.2010.100378.Verri W.A., Souto F.O., Vieira S.M., Almeida S.C.L., Fukada S.Y., Xu D., Alves- Filho J.C., Cunha T.M., Guerrero A.T., Mattos-Guimaraes R.B., Oliveira F.R., Teixeira M.M., Silva J.S., McInnes I.B., Ferreira S.H., Louzada-Junior P., Liew F.Y., Cunha F.Q. IL- 33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy. Ann. Rheum. Dis. 2010; 69 (9): 1697–1703. DOI: 10.1136/ard.2009.122655.Molofsky A.B., Savage A.K., Locksley R.M. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity. 2015; 42 (6): 1005–1019. DOI: 10.1016/j.immuni.2015.06.006.Cui G., Qi H., Gundersen M.D., Yang H., Christiansen I., Sørbye S.W., Goll R., Florholmen J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol. Immunother. 2015; 64 (2): 181–190. DOI: 10.1007/s00262-014-1624-x.Sawada H., Naito Y., Hirotani S., Akahori H., Iwasaku T., Okuhara Y., Miki K., Eguchi A., Mitsuno M., Miyamoto Y., Ohyanagi M., Tsujino T., Masuyama T. Expression of interleukin-33 and ST2 in nonrheumatic aortic valve stenosis. International Journal of Cardiology. 2013; 168 (1): 529–630. DOI: 10.1016/j.ijcard.2012.12.059.Fu A.K., Hung K.W., Yuen M.Y., Zhou X., Mak D.S., Chan I.C., Cheung T.H., Zhang B., Fu W.Y., Liew F.Y., Ip N.Y. IL-33 ameliorates Alzheimer’s disease-like pathology and cognitive decline. PNAS. 2016; 113 (19): e2705–2713. DOI: 10.1073/pnas.1604032113.Demyanets S., Speidl W.S., Tentzeris I., Jarai R., Katsaros K.M., Farhan S., Krychtiuk K.A., Wonnerth A., Weiss T.W., Huber K., Wojta J. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014; 9 (4): e95055. DOI: 10.1371/journal.pone.0095055.Theoharides T.C., Zhang B., Kempuraj D., Tagen M., Vasiadi M., Angelidou A., Alysandratos K.D., Kalogeromitros D., Asadi S., Stavrianeas N., Peterson E., Leeman S., Conti P IL-33 augments substance p-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA. 2010; 107 (9): 4448–4453. DOI: 10.1073/pnas.1000803107.Mok M.Y., Huang F.P., Ip W.K., Lo Y., Wong F.Y., Chan E.Y., Lam K.F., Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2010; 49 (3): 520–527. DOI: 10.1093/rheumatology/kep402.Queiroz G.A., Costa R.S., Alcantara-Neves N.M., Barreto M.L., Carneiro V.L., Figueredo C.A. IL33 and IL1RL1 variants are associated with asthma and atopy in a Brazilian population. Int. J. Immunogenet. 2017; 44 (2): 51–61. DOI: 10.1111/iji.12306. DOI: 10.1111/iji.12306.Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., Oh H.J., Heo Y.J., Park S.H., Kim H.Y., Min J.K. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. Journal of Korean Medical Science. 2011; 26 (9): 1132–1139. DOI: 10.3346/jkms.2011.26.9.1132.Дылева Ю.А., Груздева О.В., Акбашева О.Е., Учасова Е.Г., Барбараш О.Л. Физиологическая и патофизиологическая роль стимулирующего фактора роста ST2. Клиническая лабораторная диагностика. 2017; 62 (10): 599–605. DOI: 10.18821/0869-2084-2017-62-10-599-605.Demyanets S., Kaun C., Pentz R., Krychtiuk K., Rauscher S., Pfaffenberger S., Zuckermann A., Aliabadi A., Gröger M., Maurer G., Huber K., Wojta J. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. Journal of Molecular and Cellular Cardiology. 2013; 60: 16–26. DOI: 10.1016/j.yjmcc.2013.03.020.Sponheim J., Pollheimer J., Olsen T., Balogh J., Hammarstrome C., Loos T., Kasprzycka M., Sørensen D.R., Nilsen H.R., Küchler A.M., Vatn M.H., Haraldsen G. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 2010; 177 (6): 2804–2815. DOI: 10.2353/ajpath.2010.100378.Jans C., Boleij A. The road to infection: Host-microbe interactions defining the pathogenicity of Streptococcus bovis/ Streptococcus equinus complex members. Front. Microbiol. 2018; 9: 603. DOI: 10.3389/fmicb.2018.00603.Molofsky A.B., Savage A.K., Locksley R.M. Interleukin-33 in tissue homeostasis, injury, and inflammation. Immunity. 2015; 42 (6): 1005–1019. DOI: 10.1016/j.immuni.2015.06.006.Xu J., Zheng J., Song P., Zhou Y., Guan S. IL-33/ST2 pathway in a bleomycin-induced pulmonary fibrosis model. Mol. Med. Rep. 2016; 14 (2): 1704–1708. DOI: 10.3892/mmr.2016.5446.Sawada H., Naito Y., Hirotani S., Akahori H., Iwasaku T., Okuhara Y., Miki K., Eguchi A., Mitsuno M., Miyamoto Y., Ohyanagi M., Tsujino T., Masuyama T. Expression of interleukin-33 and ST2 in nonrheumatic aortic valve stenosis. International Journal of Cardiology. 2013; 168 (1): 529–630. DOI: 10.1016/j.ijcard.2012.12.059.Akimoto M., Hayashi J.-I., Nakae S., Saito H., Takenaga K.. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016; 7: e2057. DOI: 10.1038/cddis.2015.418.Demyanets S., Speidl W.S., Tentzeris I., Jarai R., Katsaros K.M., Farhan S., Krychtiuk K.A., Wonnerth A., Weiss T.W., Huber K., Wojta J. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014; 9 (4): e95055. DOI: 10.1371/journal.pone.0095055.Salmond R.J., Mirchandani A.S., Besnard A.G., Bain C.C., Thomson N.C., Liew F.Y. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J. Allergy Clin. Immunol. 2012; 130 (5): 1159–1166. DOI: 10.1016/j.jaci.2012.05.018.Mok M.Y., Huang F.P., Ip W.K., Lo Y., Wong F.Y., Chan E.Y., Lam K.F., Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2010; 49 (3): 520–527. DOI: 10.1093/rheumatology/kep402.Hong K., Lee Y., Lee S., Hong S., Bae S., Hong J., Bae S., Hong J., Choi J., Jhun H., Kwak A., Kim E., Jo S., Kang T., Cho Y.S., Kim Y.G., Kim S. The inhibitory function of FcST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity. Immunol. Res. 2013; 56 (1): 122–130. DOI: 10.1007/s12026-013-8388-9.Hong Y.S., Moon S.J., Joo Y.B., Jeon C.H., Cho M.L., Ju J.H., Oh H.J., Heo Y.J., Park S.H., Kim H.Y., Min J.K. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. Journal of Korean Medical Science. 2011; 26 (9): 1132–1139. DOI: 10.3346/jkms.2011.26.9.1132.Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., Min B., Kastelein R.A., Aronica M., Kosz-Vnenchak M., Li X. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J. Immunol. 2009; 182 (5): 2601–2609. DOI: 10.4049/jimmunol.0802729.Demyanets S., Kaun C., Pentz R., Krychtiuk K., Rauscher S., Pfaffenberger S., Zuckermann A., Aliabadi A., Gröger M., Maurer G., Huber K., Wojta J. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. Journal of Molecular and Cellular Cardiology. 2013; 60: 16–26. DOI: 10.1016/j.yjmcc.2013.03.020.Reichenbach D.K., Schwarze V., Matta B.M., Tkachev V., Lieberknecht E., Liu Q., Koehn B.H., Pfeifer D., Taylor P.A., Prinz G., Dierbach H., Stickel N., Beck Y., Warncke M., Junt T., Schmitt-Graeff A., Nakae S., Follo M., Wertheimer T., Schwab L., Devlin J., Watkins S.C., Duyster J., Ferrara J.L., Turnquist H.R., Zeiser R., Blazar B.R. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015; 125 (20): 3183–3192. DOI: 10.1182/blood-2014-10-606830.Jans C., Boleij A. The road to infection: Host-microbe interactions defining the pathogenicity of Streptococcus bovis/ Streptococcus equinus complex members. Front. Microbiol. 2018; 9: 603. DOI: 10.3389/fmicb.2018.00603.Imai Y., Yasuda K., Sakaguchi Y., Haneda T., Mizutani H., Yoshimoto T., Nakanishi K., Yamanishi K. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. USA. 2013; 110 (34): 13921–13926. DOI: 10.1073/pnas.1307321110.Xu J., Zheng J., Song P., Zhou Y., Guan S. IL-33/ST2 pathway in a bleomycin- induced pulmonary fibrosis model. Mol. Med. Rep. 2016; 14 (2): 1704–1708. DOI: 10.3892/mmr.2016.5446.Miller J.E., Monsanto S.P., Ahn S.H., Khalaj K., Fazleabas A.T., Young S.L., Lessey B.A., Koti M., Tayade C. Interleukin-33 modulates inflammation in endometriosis. Sci. Rep. 2017; 7 (1): 17903. DOI: 10.1038/s41598-017-18224-x.Akimoto M., Hayashi J.-I., Nakae S., Saito H., Takenaga K.. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016; 7: e2057. DOI: 10.1038/cddis.2015.418.Kearley J., Silver J.S., Sanden C., Liu Z., Berlin A.A., White N., Mori M., Pham T.H., Ward C.K., Criner G.J., Marchetti N., Mustelin T., Erjefalt J.S., Kolbeck R., Humbles A.A. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 2015; 42 (3): 566–579. DOI: 10.1016/j.immuni.2015.02.011.Salmond R.J., Mirchandani A.S., Besnard A.G., Bain C.C., Thomson N.C., Liew F.Y. IL-33 induces innate lymphoid cell-mediated airway inflammation by activating mammalian target of rapamycin. J. Allergy Clin. Immunol. 2012; 130 (5): 1159–1166. DOI: 10.1016/j.jaci.2012.05.018.Barbour M., Allan D., Xu H., Pei C., Chen M., Niedbala W., Fukada S.Y., Besnard A.G., Alves-Filho J.C., Tong X., Forrester J.V., Liew F.Y., Jiang H.R. IL-33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 2014; (44): 3320–3329. DOI: 10.1002/eji.201444671.Hong K., Lee Y., Lee S., Hong S., Bae S., Hong J., Bae S., Hong J., Choi J., Jhun H., Kwak A., Kim E., Jo S., Kang T., Cho Y.S., Kim Y.G., Kim S. The inhibitory function of FcST2 depends on cell type; IL-1RAcP and ST2 are necessary but insufficient for IL-33 activity. Immunol. Res. 2013; 56 (1): 122–130. DOI: 10.1007/s12026-013-8388-9.Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the International ST2 Consensus Panel. Am. J. Cardiol. 2015; 115 (7): 3B–7B. DOI: 10.1016/j.amjcard.2015.01.034.Bulek K., Swaidani S., Qin J., Lu Y., Gulen M.F., Herjan T., Min B., Kastelein R.A., Aronica M., Kosz-Vnenchak M., Li X. The essential role of single Ig IL-1 receptor-related molecule/Toll IL-1R8 in regulation of Th2 immune response. J. Immunol. 2009; 182 (5): 2601–2609. DOI: 10.4049/jimmunol.0802729.Sanchez-Mas J., Lax A., Asensio-López Mdel C., Fernandez-Del Palacio M.J., Caballero L., Santarelli G., Januzzi J.L., Pascual-Figal D.A. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur. J. Clin. Inves. 2014; 44 (7): 643–651. DOI: 10.1111/eci.12282.Reichenbach D.K., Schwarze V., Matta B.M., Tkachev V., Lieberknecht E., Liu Q., Koehn B.H., Pfeifer D., Taylor P.A., Prinz G., Dierbach H., Stickel N., Beck Y., Warncke M., Junt T., Schmitt-Graeff A., Nakae S., Follo M., Wertheimer T., Schwab L., Devlin J., Watkins S.C., Duyster J., Ferrara J.L., Turnquist H.R., Zeiser R., Blazar B.R. The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. Blood. 2015; 125 (20): 3183–3192. DOI: 10.1182/blood-2014-10-606830.Ho J.E., Chen W.Y., Chen M.H., Larson M.G., McCabe E.L., Cheng S., Ghorbani A., Coglianese E., Emilsson V., Johnson A.D., Walter S., Franceschini N., O’Donnell C.J.; CARDIoGRAM Consortium; CHARGE Inflammation Working Group, Dehghan A., Lu C., Levy D., Newton-Cheh C.; CHARGE Heart Failure Working Group, Lin H., Felix J.F., Schreiter E.R., Vasan R.S., Januzzi J.L., Lee R.T., Wang T.J. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J. Clin. Invest. 2013; 123 (10): 4208–4218. DOI: 10.1172/JCI67119.Imai Y., Yasuda K., Sakaguchi Y., Haneda T., Mizutani H., Yoshimoto T., Nakanishi K., Yamanishi K. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. USA. 2013; 110 (34): 13921–13926. DOI: 10.1073/pnas.1307321110.Yang J.H., Wu F.Q., Wen Q., Zhang W.C., Wang Y.E., Xiong X., Su Y.W., Cheng L.X. Association of IL33/ST2 signal pathway gene polymorphisms with myocardial infarction in a Chinese Han population. J. Huazhong. Univ. Sci Technology Med. Sci. 2015; 35 (1): 16–20. DOI: 10.1007/s11596-015-1382-9.Miller J.E., Monsanto S.P., Ahn S.H., Khalaj K., Fazleabas A.T., Young S.L., Lessey B.A., Koti M., Tayade C. Interleukin-33 modulates inflammation in endometriosis. Sci. Rep. 2017; 7 (1): 17903. DOI: 10.1038/s41598-017-18224-x.Schwartz C., O’Grady K., Lavelle E.C., Fallon P.G. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur. J. Immunol. 2016; 46 (5): 1091–1100. DOI: 10.1002/eji.201545780.Kearley J., Silver J.S., Sanden C., Liu Z., Berlin A.A., White N., Mori M., Pham T.H., Ward C.K., Criner G.J., Marchetti N., Mustelin T., Erjefalt J.S., Kolbeck R., Humbles A.A. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity. 2015; 42 (3): 566–579. DOI: 10.1016/j.immuni.2015.02.011.Chen Y., Qian J. Increased serum levels of IL-33 and soluble ST2 in neonates with human cytomegalovirus infection. J. Med. Virol. 2018; 90 (8): 1383–1388. DOI: 10.1002/jmv.25187.Barbour M., Allan D., Xu H., Pei C., Chen M., Niedbala W., Fukada S.Y., Besnard A.G., Alves-Filho J.C., Tong X., Forrester J.V., Liew F.Y., Jiang H.R. IL-33 attenuates the development of experimental autoimmune uveitis. Eur. J. Immunol. 2014; (44): 3320–3329. DOI: 10.1002/eji.201444671.Yanagisawa K., Naito Y., Kuroiwa K., Arai T., Furukawa Y., Tomizuka H., Miura Y., Kasahara T., Tetsuka T., Tominaga S. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. The Journal of Biochemistry. 1997; 121 (1): 95–103. DOI: 10.1093/oxfordjournals.jbchem.a021577.Pascual-Figal D.A., Januzzi J.L. The biology of ST2: the International ST2 Consensus Panel. Am. J. Cardiol. 2015; 115 (7): 3B–7B. DOI: 10.1016/j.amjcard.2015.01.034.Zhu J., Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine. 2012; 58 (3): 368–379. DOI: 10.1016/j.cyto.2012.02.008.Sanchez-Mas J., Lax A., Asensio-López Mdel C., Fernandez-Del Palacio M.J., Caballero L., Santarelli G., Januzzi J.L., Pascual-Figal D.A. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. Eur. J. Clin. Inves. 2014; 44 (7): 643–651. DOI: 10.1111/eci.12282.Shao D., Perros F., Caramori G., Meng C., Dormuller P., Chou P.C., Church C., Papi A., Casolari P., Welsh D., Peacock A., Humbert M., Adcock I.M, Wort S.J. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications. 2014; 451 (1): 8–14. DOI: 10.1016/j.bbrc.2014.06.111.Ho J.E., Chen W.Y., Chen M.H., Larson M.G., McCabe E.L., Cheng S., Ghorbani A., Coglianese E., Emilsson V., Johnson A.D., Walter S., Franceschini N., O’Donnell C.J.; CARDIoGRAM Consortium; CHARGE Inflammation Working Group, Dehghan A., Lu C., Levy D., Newton-Cheh C.; CHARGE Heart Failure Working Group, Lin H., Felix J.F., Schreiter E.R., Vasan R.S., Januzzi J.L., Lee R.T., Wang T.J. Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J. Clin. Invest. 2013; 123 (10): 4208–4218. DOI: 10.1172/JCI67119.Veeraveedu P.T., Sanada S., Okuda K., Fu H.Y., Matsuzaki T., Araki R., Yamato M., Yasuda K., Sakata Y., Yoshimoto T., Minamino T. Ablation IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochemical Pharmacology. 2017; 138: 73–80. DOI: 10.1016/j.bcp.2017.04.022.Yang J.H., Wu F.Q., Wen Q., Zhang W.C., Wang Y.E., Xiong X., Su Y.W., Cheng L.X. Association of IL33/ST2 signal pathway gene polymorphisms with myocardial infarction in a Chinese Han population. J. Huazhong. Univ. Sci Technology Med. Sci. 2015; 35 (1): 16–20. DOI: 10.1007/s11596-015-1382-9.Reverchon F., Mortaud S., Sivoyon M., Maillet I., Laugeray A., Palomo J., Montécot C., Herzine A., Meme S., Meme W., Erard F., Ryffel B., Menuet A., Quesniaux V.F.J. Quesniaux IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS Pathog. 2017; 13 (4): e1006322. DOI: 10.1371/journal.ppat.1006322.Schwartz C., O’Grady K., Lavelle E.C., Fallon P.G. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur. J. Immunol. 2016; 46 (5): 1091–1100. DOI: 10.1002/eji.201545780.Schwartz C., O’Grady K., Lavelle E.C., Fallon P.G. Interleukin 33: an innate alarm for adaptive responses beyond Th2 immunity-emerging roles in obesity, intestinal inflammation, and cancer. Eur. J. Immunol. 2016; 46 (5): 1091–1100. DOI: 10.1002/eji.201545780.Chen Y., Qian J. Increased serum levels of IL-33 and soluble ST2 in neonates with human cytomegalovirus infection. J. Med. Virol. 2018; 90 (8): 1383–1388. DOI: 10.1002/jmv.25187.Chen Y., Qian J. Increased serum levels of IL-33 and soluble ST2 in neonates with human cytomegalovirus infection. J. Med. Virol. 2018; 90 (8): 1383–1388. DOI: 10.1002/jmv.25187.Yanagisawa K., Naito Y., Kuroiwa K., Arai T., Furukawa Y., Tomizuka H., Miura Y., Kasahara T., Tetsuka T., Tominaga S. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. The Journal of Biochemistry. 1997; 121 (1): 95–103. DOI: 10.1093/oxfordjournals.jbchem.a021577.Yanagisawa K., Naito Y., Kuroiwa K., Arai T., Furukawa Y., Tomizuka H., Miura Y., Kasahara T., Tetsuka T., Tominaga S. The expression of ST2 gene in helper T cells and the binding of ST2 protein to myeloma-derived RPMI8226 cells. The Journal of Biochemistry. 1997; 121 (1): 95–103. DOI: 10.1093/oxfordjournals.jbchem.a021577.Zhu J., Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine. 2012; 58 (3): 368–379. DOI: 10.1016/j.cyto.2012.02.008.Zhu J., Carver W. Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine. 2012; 58 (3): 368–379. DOI: 10.1016/j.cyto.2012.02.008.Shao D., Perros F., Caramori G., Meng C., Dormuller P., Chou P.C., Church C., Papi A., Casolari P., Welsh D., Peacock A., Humbert M., Adcock I.M, Wort S.J. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications. 2014; 451 (1): 8–14. DOI: 10.1016/j.bbrc.2014.06.111.Shao D., Perros F., Caramori G., Meng C., Dormuller P., Chou P.C., Church C., Papi A., Casolari P., Welsh D., Peacock A., Humbert M., Adcock I.M, Wort S.J. Nuclear IL-33 regulates soluble ST2 receptor and IL-6 expression in primary human arterial endothelial cells and is decreased in idiopathic pulmonary arterial hypertension. Biochemical and Biophysical Research Communications. 2014; 451 (1): 8–14. DOI: 10.1016/j.bbrc.2014.06.111.Veeraveedu P.T., Sanada S., Okuda K., Fu H.Y., Matsuzaki T., Araki R., Yamato M., Yasuda K., Sakata Y., Yoshimoto T., Minamino T. Ablation IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochemical Pharmacology. 2017; 138: 73–80. DOI: 10.1016/j.bcp.2017.04.022.Veeraveedu P.T., Sanada S., Okuda K., Fu H.Y., Matsuzaki T., Araki R., Yamato M., Yasuda K., Sakata Y., Yoshimoto T., Minamino T. Ablation IL-33 gene exacerbate myocardial remodeling in mice with heart failure induced by mechanical stress. Biochemical Pharmacology. 2017; 138: 73–80. DOI: 10.1016/j.bcp.2017.04.022.Reverchon F., Mortaud S., Sivoyon M., Maillet I., Laugeray A., Palomo J., Montécot C., Herzine A., Meme S., Meme W., Erard F., Ryffel B., Menuet A., Quesniaux V.F.J. Quesniaux IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS Pathog. 2017; 13 (4): e1006322. DOI: 10.1371/journal.ppat.1006322.Reverchon F., Mortaud S., Sivoyon M., Maillet I., Laugeray A., Palomo J., Montécot C., Herzine A., Meme S., Meme W., Erard F., Ryffel B., Menuet A., Quesniaux V.F.J. Quesniaux IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria. PLoS Pathog. 2017; 13 (4): e1006322. DOI: 10.1371/journal.ppat.1006322.

The authors declare that there are no conflicts of interest present.